Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Conditions

Subcategories:Axial SpondyloarthritisClinical Criteria/GuidelinesGout and Crystalline ArthritisMyositisOsteoarthritis and Bone DisordersOther Rheumatic ConditionsPain SyndromesPediatric ConditionsPsoriatic ArthritisRheumatoid ArthritisSjögren’s DiseaseSoft Tissue PainSystemic Lupus ErythematosusSystemic SclerosisVasculitis

Oral Treatment for PsA Inches Closer to FDA Approval

Michele B. Kaufman, PharmD, BCGP  |  September 15, 2025

The FDA will consider a supplemental new drug application for deucravacitinib for the treatment of adults with active psoriatic arthritis based on promising results from clinical trials.

A New Treatment for Fibromyalgia?

Michele B. Kaufman, PharmD, BCGP  |  September 11, 2025

The FDA has approved a new drug application for TNX-102 SL (Tonmya), a tablet with 2.8 mg of cyclobenzaprine HCl, after two clinical trials demonstrated the safety and effectiveness of the treatment in adults with fibromyalgia.

Rethinking Lupus Nephritis: Are Current Approaches & Guidelines off Target?

Mithu Maheswaranathan, MD  |  September 9, 2025

A rheumatologist & lupus expert reviews lupus nephritis treatment, questioning proteinuria cutoffs & ACR guidelines, advocating for newer therapies & end-of-treatment biopsies.

10 Things to Know about Lupus

Mithu Maheswaranathan, MD  |  September 8, 2025

SLE treatment is rapidly evolving as new therapies are developed & approved. Here are 10 key insights for clinicians.

3 AC&R Study Summaries: Avoidable RA Hospitalizations, Psoriasis to Psoriatic Arthritis Transition, & Neighborhood Conditions in Childhood Lupus

Arthritis Care & Research  |  September 8, 2025

New studies reveal predictors for avoidable RA hospitalizations, PsA transition in psoriasis & the impact of neighborhood on childhood lupus.

Case Reports: Mimics of Polyarteritis Nodosa

Shane Murray, BMBS, RhMSUS, Zhe Ran Duan, MD, PhD, & Daniel DeMizio, MD  |  September 8, 2025

When polyarteritis nodosa isn’t PAN: Two cases of mimics, segmental arterial mediolysis (SAM) & vascular Ehlers-Danlos syndrome (vEDS), are explored.

Cardiovascular Risks Similar for JAK Inhibitors & bDMARDs

Arthritis & Rheumatology  |  August 26, 2025

Using data from registries across Europe and Canada, Aymon et al. compared the incidence of major adverse cardiac events (MACE) in patients with RA treated with JAK inhibitors, TNF inhibitors or biologic DMARDs with other modes of action over two years. The researchers did not find an increased risk of MACE with JAK inhibitors over that time frame.

Mouth-Watering Possibilities in Sjögren’s Disease

Colin Ligon, MD, MHS  |  August 26, 2025

New ACR guidelines for SARD-associated interstitial lung disease cover key recommendations for screening, monitoring and first-line treatment options.

Sjögren’s Disease: More Than Just a Syndrome

Jason Liebowitz, MD, FACR  |  August 26, 2025

A EULAR 2025 review of Sjögren’s disease covered new pathogenic insights & promising phase 2 data for BTK inhibitors & CD40 pathway drugs.

How to Diagnose Sjögren’s Disease

Samantha C. Shapiro, MD  |  August 26, 2025

Improve your Sjögren’s disease diagnosis. Experts discuss objective testing, seronegative cases, ILD screening & management strategies.
  • 1
  • 2
  • 3
  • …
  • 344
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences